Research Article

The seroprevalence of hepatitis A in Istanbul, Turkey

Volume: 30 Number: 1 January 15, 2017
  • Aslı Karadeniz
  • Elçin Akduman Alaşehir
  • Zuhal Yeşilbağ
  • Ahmet Balıkçı
  • Görkem Yaman
EN

The seroprevalence of hepatitis A in Istanbul, Turkey

Abstract

Objective: Hepatitis A, a leading cause of enterically transmitted

acute viral hepatitis throughout the world, has changed its pattern

in developing countries. The objective of this study is to determine

the current seroprevalence of hepatitis A virus (HAV) for different

age groups in Istanbul, Turkey.

Material and Methods: Serum samples of 3,868 patients,

which had been previously taken, were used to determine anti-HAV

IgG levels by the microparticle enzyme immunoassay (MPEIA)

method (Architect SR i1000 and i2000, Abbott Diagnostics,

Germany) between January 2011 and December 2013.

Results: The prevalence of total anti-HAV antibodies was

64.8% for all patients. Among the 3,868 serum samples tested,

54% were from male patients and 46 % were from female patients.

Seropositivity rates among the age groups were determined and anti-

HAV antibody positivity rates were 55% for the 0-16 age group;

47% for the 17-30 age group; 73.5% for the 31-45 age group and the

seroprevalence increased significantly from 50% (972/1944) in 0 to

30 years old to 89% in patients older than 46 years.

Conclusion: The low seronegativity rates in young adults,

show this group to be at high risk of acquiring an HAV infection.

The results support the routine vaccination of children and the

seronegative young adults against HAV.

Keywords

References

  1. Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL,
  2. Bennett JE, Dolin R, editors. Hepatitis A. Mandell, Douglas,
  3. and Bennett’s Principles and Practice of Infectious Diseases.
  4. 6th ed. Philadelphia: Churchill Livingstone, 2005:1426-40.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Authors

Aslı Karadeniz This is me
Türkiye

Elçin Akduman Alaşehir This is me
Türkiye

Zuhal Yeşilbağ This is me
Türkiye

Ahmet Balıkçı This is me
Türkiye

Görkem Yaman This is me
Türkiye

Publication Date

January 15, 2017

Submission Date

March 22, 2017

Acceptance Date

December 11, 2016

Published in Issue

Year 2017 Volume: 30 Number: 1

APA
Karadeniz, A., Akduman Alaşehir, E., Yeşilbağ, Z., Balıkçı, A., & Yaman, G. (2017). The seroprevalence of hepatitis A in Istanbul, Turkey. Marmara Medical Journal, 30(1), 14-17. https://doi.org/10.5472/marumj.299380
AMA
1.Karadeniz A, Akduman Alaşehir E, Yeşilbağ Z, Balıkçı A, Yaman G. The seroprevalence of hepatitis A in Istanbul, Turkey. Marmara Med J. 2017;30(1):14-17. doi:10.5472/marumj.299380
Chicago
Karadeniz, Aslı, Elçin Akduman Alaşehir, Zuhal Yeşilbağ, Ahmet Balıkçı, and Görkem Yaman. 2017. “The Seroprevalence of Hepatitis A in Istanbul, Turkey”. Marmara Medical Journal 30 (1): 14-17. https://doi.org/10.5472/marumj.299380.
EndNote
Karadeniz A, Akduman Alaşehir E, Yeşilbağ Z, Balıkçı A, Yaman G (January 1, 2017) The seroprevalence of hepatitis A in Istanbul, Turkey. Marmara Medical Journal 30 1 14–17.
IEEE
[1]A. Karadeniz, E. Akduman Alaşehir, Z. Yeşilbağ, A. Balıkçı, and G. Yaman, “The seroprevalence of hepatitis A in Istanbul, Turkey”, Marmara Med J, vol. 30, no. 1, pp. 14–17, Jan. 2017, doi: 10.5472/marumj.299380.
ISNAD
Karadeniz, Aslı - Akduman Alaşehir, Elçin - Yeşilbağ, Zuhal - Balıkçı, Ahmet - Yaman, Görkem. “The Seroprevalence of Hepatitis A in Istanbul, Turkey”. Marmara Medical Journal 30/1 (January 1, 2017): 14-17. https://doi.org/10.5472/marumj.299380.
JAMA
1.Karadeniz A, Akduman Alaşehir E, Yeşilbağ Z, Balıkçı A, Yaman G. The seroprevalence of hepatitis A in Istanbul, Turkey. Marmara Med J. 2017;30:14–17.
MLA
Karadeniz, Aslı, et al. “The Seroprevalence of Hepatitis A in Istanbul, Turkey”. Marmara Medical Journal, vol. 30, no. 1, Jan. 2017, pp. 14-17, doi:10.5472/marumj.299380.
Vancouver
1.Aslı Karadeniz, Elçin Akduman Alaşehir, Zuhal Yeşilbağ, Ahmet Balıkçı, Görkem Yaman. The seroprevalence of hepatitis A in Istanbul, Turkey. Marmara Med J. 2017 Jan. 1;30(1):14-7. doi:10.5472/marumj.299380

Cited By